Review
Oncology
Wei Zhang, Bixiang Zhang, Xiao-ping Chen
Summary: Several adjuvant treatments have been evaluated for preventing HCC recurrence after curative liver resection, with antiviral therapy and postoperative adjuvant transarterial chemoembolization showing promising results. However, further large-scale randomized controlled trials are needed to confirm their efficacy in different patient populations.
FRONTIERS OF MEDICINE
(2021)
Article
Multidisciplinary Sciences
Liming Zheng, Xi Gu, Guojun Zheng, Xin Li, Meifang He, Longgen Liu, Xike Zhou
Summary: The study constructed a predictive model using various analysis methods to successfully identify high-risk patients for early HCC recurrence, and predict patients' response to adjuvant sorafenib treatment. The model can optimize risk stratification for early HCC recurrence and evaluate patient response to adjuvant sorafenib after liver resection.
Review
Oncology
Shenglan Huang, Dan Li, LingLing Zhuang, Liying Sun, Jianbing Wu
Summary: This meta-analysis explored the efficacy and safety of sorafenib in hepatocellular carcinoma patients after radical surgery, revealing that sorafenib can improve overall survival, recurrence-free survival, and reduce recurrence rates without intolerable side effects. More evidence is needed for a definitive conclusion.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2021)
Article
Oncology
Changying Shi, Yong Li, Li Geng, Weifeng Shen, Chengjun Sui, Binghua Dai, Jiongjiong Lu, Mianshun Pan, Jiamei Yang
Summary: This study aimed to investigate the efficacy of SBRT targeting suboptimal resection margin as adjuvant therapy in MVI-positive HCC. The results showed that SBRT group had significantly better DFS and OS compared to the surgery alone group.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Oncology
Shilei Bai, Lei Hu, Jianwei Liu, Minmin Sun, Yanfu Sun, Feng Xue
Summary: This study investigated the potential effect of postoperative adjuvant therapy with lenvatinib on the long-term prognosis of hepatitis B virus-related hepatocellular carcinoma with microvascular invasion (MVI). The results showed that patients who received postoperative lenvatinib had improved recurrence rates and survival rates compared to those who did not receive the treatment. Nomograms were also used to accurately predict long-term survival.
FRONTIERS IN ONCOLOGY
(2022)
Review
Oncology
Xu Feng, Guo-Ying Feng, Jie Tao, Yu-Pei Ao, Xin-Hua Wu, Shi-Guai Qi, Zheng-Rong Shi
Summary: In this network meta-analysis, we found that postoperative adjuvant local therapies and molecular targeted therapies significantly improved overall survival (OS) and disease-free survival (DFS) in hepatocellular carcinoma (HCC) patients with a high risk of recurrence after radical resection. Specifically, postoperative adjuvant radiotherapy showed the best efficacy in terms of DFS, while molecular targeted therapy demonstrated the best efficacy in terms of OS.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Qingli Li, Tianqiang Song
Summary: Although adjuvant sorafenib therapy for patients with HCC and high recurrence risk does not reduce the recurrence risk of HCC, it might be associated with longer survival and a lower risk of death.
FRONTIERS IN ONCOLOGY
(2021)
Article
Medicine, General & Internal
Hamzah Adwan, Lars Hammann, Thomas J. Vogl
Summary: This study evaluated the efficacy and safety of microwave ablation (MWA) as a treatment for recurrent hepatocellular carcinoma (HCC) after initial surgical resection. The results showed that MWA treatment is effective and safe for recurrent HCC lesions.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Gustavo R. Sarria, Solon Serpa, Mario Buitrago, Paola Fuentes Rivera, Diego Ramirez, Frank A. Giordano, Gustavo J. Sarria
Summary: A retrospective study evaluated the use of single-fraction adjuvant electronic brachytherapy (e-BT) for squamous cell conjunctival carcinoma (SCCC), showing that it is a safe and effective treatment with clinical and logistical advantages compared to traditional methods. Further research with longer follow-up and prospective assessment is needed.
Article
Medicine, Research & Experimental
Pan He, En Ren, Biaoqi Chen, Hu Chen, Hongwei Cheng, Xing Gao, Xiaoliu Liang, Hao Liu, Jingdong Li, Bo Li, Aizheng Chen, Chengchao Chu, Xiaoyuan Chen, Jingsong Mao, Yang Zhang, Gang Liu
Summary: The lipiodol formulations used in TACE are limited by insufficient physical stability, but this study successfully dispersed the hydrophilic drug in lipiodol using nanotechnology, leading to improved therapeutic outcomes and increased safety.
Article
Gastroenterology & Hepatology
Yanyan Ye, Ying Wang, Haoqian Xu, Fengming Yi
Summary: This study conducted a network meta-analysis to compare the efficacy of different treatments for preventing recurrence and prolonging survival in hepatocellular carcinoma patients. The results showed that transarterial chemoembolization (TACE) + portal vein chemotherapy (PVC) and internal radiotherapy (IRT) were effective in reducing recurrence rate, while TACE, IRT, and dendritic cell (DC) treatments showed benefits in extending the patients' survival time.
BMC GASTROENTEROLOGY
(2023)
Article
Oncology
Zhancheng Qiu, Weili Qi, Youwei Wu, Lingling Li, Chuan Li
Summary: This study examines the impact of public insurance status on the survival outcomes of HCC patients after liver resection in China. The results show that underinsured HCC patients have worse survival outcomes after liver resection. This may be due to the limited access to care for underinsured patients, but further exploration is needed for conclusive evidence.
Article
Engineering, Chemical
Christelle Bouvry, Valerie Ardisson, Nicolas Noiret, Etienne Garin, Nicolas Lepareur
Summary: Hepatocellular carcinoma (HCC), the most common primary liver tumor, ranks fifth in incidence and third in mortality worldwide. Despite advancements in treatment, prognosis for HCC remains poor. Transarterial radioembolization with radiolabeled microspheres and Lipiodol shows significant effectiveness.
Review
Oncology
Flavio Milana, Michela Anna Polidoro, Simone Famularo, Ana Lleo, Renzo Boldorini, Matteo Donadon, Guido Torzilli
Summary: Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and both liver resection and liver transplantation are considered potentially curative options. The management of HCC recurrence is still not well defined, but surgery remains a curative option for selected patients. This study aimed to summarize the patterns and histopathological characteristics of HCC recurrence, their prognostic value, and the main surgical strategies for dealing with HCC relapse.
Article
Radiology, Nuclear Medicine & Medical Imaging
Fei Wu, Haitao Sun, Changwu Zhou, Peng Huang, Yuyao Xiao, Chun Yang, Mengsu Zeng
Summary: This study evaluated whether radiological similarity and clinicopathological factors determine the prognosis in bifocal hepatocellular carcinoma (bHCC) stratified by the Milan criteria. The study found that the radiological similarity of bHCC lesions is associated with long-term prognosis, in addition to other factors.
EUROPEAN RADIOLOGY
(2023)
Article
Nutrition & Dietetics
David L. Chan, Stephen J. Clarke, Alexander Engel, Connie I. Diakos, Nick Pavlakis, Paul J. Roach, Dale L. Bailey, Judith Bauer, Merran Findlay
Summary: The study found that sarcopenia and myosteatosis are common in NEN patients but were not associated with worsened survival outcomes in this study.
EUROPEAN JOURNAL OF CLINICAL NUTRITION
(2022)
Article
Oncology
Derrick Ho Wai Siu, Arwa Ali, Angelina Tjokrowidjaja, Madhawa De Silva, Joanna Lee, Philip R. Clingan, Morteza Aghmesheh, Daniel Brungs, Cristina Mapagu, David Goldstein, Siobhan O'Neill, Winston S. Liauw, Katrin M. Sjoquist, David Thomas, Nick Pavlakis, Stephen J. Clarke, Connie Diakos, Lorraine A. Chantrill
Summary: This study aimed to determine the demographic, histopathological and molecular characteristics of patients with early-onset colorectal cancer (EO-CRC) in Australia, as well as their survival. The results showed that some patients already presented with metastatic disease, and pathological risk factors and molecular mutations affected the survival of the patients.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Medicine, General & Internal
Melanie R. Lovell, Jane L. Phillips, Tim Luckett, Lawrence Lam, Frances M. Boyle, Patricia M. Davidson, Seong L. Cheah, Nicola McCaffrey, David C. Currow, Tim Shaw, Annmarie Hosie, Bogda Koczwara, Stephen Clarke, Jessica Lee, Martin R. Stockler, Caitlin Sheehan, Odette Spruijt, Katherine Allsopp, Alexandra Clinch, Katherine Clark, Alison Read, Meera Agar
Summary: This study evaluated the effectiveness of three cancer pain guideline implementation strategies on improving pain outcomes for patients in oncology and palliative care outpatient services. The results showed that these strategies had limited impact on pain-related outcomes and further evaluation and improvement are needed.
Review
Oncology
Keenan Whittle, Steven Kao, Stephen Clarke, Georges E. R. Grau, Elham Hosseini-Beheshti
Summary: This study reviewed protein data in relevant literature to investigate the role of specific proteins in lung cancer extracellular vesicles. The findings suggest that the importance of specific proteins may vary in different types of lung cancer, but there is currently limited research on extracellular vesicle proteins in some cancers.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2022)
Article
Oncology
Malinda Itchins, Hannah Ainsworth, Marliese Alexander, Samantha Dean, Devi Dharmaraj, Nick Pavlakis, Stephen J. Clarke, Chris Brown, Javier Torres, Ayesha Saqib, Rahul Ladwa, Kenneth O'Byrne, Melissa Moore, Po Yee Yip, Ben Ben Solomon, Tom John, Steven Kao, Paul Mitchell, Sagun Parakh
Summary: Limited real world data exist on the IMpower150 regimen, and this study adds to the knowledge base by demonstrating its efficacy in EGFR mutant patients, including those with CNS metastases. The overall response rate for all patients was 51%, and for EGFR mutant patients it was 52%, highlighting the positive outcomes of this treatment approach.
CLINICAL LUNG CANCER
(2022)
Article
Oncology
Christopher B. Nahm, John Turchini, Sumit Sahni, Elizabeth Moon, Malinda Itchins, Jennifer Arena, Angela Chou, Emily K. Colvin, Viive M. Howell, Nick Pavlakis, Stephen Clarke, Jaswinder S. Samra, Anthony J. Gill, Anubhav Mittal
Summary: A triple biomarker panel can predict genetic subtypes, clinical phenotypes and optimal treatment strategies for resectable and borderline resectable pancreatic cancer.
Article
Medicine, General & Internal
Kathleen Batty, Amelia M. Taylor, Elizabeth J. Bernard, Connie Diakos, Stephen J. Clarke, Alexander Guminski, Sally Baron-Hay, Frances Boyle, Nick Pavlakis, David L. Chan
Summary: This study retrospectively analyzed a series of patients with metastatic neuroendocrine carcinoma of the breast to investigate their clinical characteristics, treatment modalities, and prognosis. The results showed that multiple treatment modalities were used with different sequencing in different patients, but the progression-free survival with first-line therapy was short.
INTERNAL MEDICINE JOURNAL
(2023)
Article
Multidisciplinary Sciences
Stephen Clarke, Belinda E. Butcher, Andrew J. McLachlan, Jeremy D. Henson, David Rutolo, Sean Hall, Luis Vitetta
Summary: This pilot study assessed the safety, tolerability, pharmacokinetics, and exploratory analgesic effect of a novel water-soluble cannabis-based medicine in patients with advanced incurable malignancy. The results showed acceptable bioavailability and preliminary evidence of analgesic efficacy, but also reported mild to moderate adverse events.
Review
Public, Environmental & Occupational Health
N. Bhimani, G. Y. M. Wong, C. Molloy, N. Pavlakis, C. I. Diakos, S. J. Clarke, M. Dieng, T. J. Hugh
Summary: This systematic review examines the direct cost of treating metastatic colorectal cancer and highlights the significant economic burden it places on healthcare systems. The review emphasizes the need for future research to define cost components and examine the relationship between spending, overall survival, and quality of life.
Article
Oncology
Maxwell A. Jambor, Amir Ashrafizadeh, Christopher B. Nahm, Stephen J. Clarke, Nick Pavlakis, Andrew Kneebone, George Hruby, Anthony J. Gill, Anubhav Mittal, Jaswinder S. Samra
Summary: This study evaluated the role of staging laparoscopy in patients with pancreatic adenocarcinoma and its impact on overall survival. The results showed that staging laparoscopy can identify metastatic lesions in a subset of patients, thus avoiding unnecessary surgeries or non-curative resections.
WORLD JOURNAL OF SURGICAL ONCOLOGY
(2022)
Article
Oncology
Johanna Bendell, Patricia LoRusso, Michael Overman, Anne M. Noonan, Dong-Wan Kim, John H. Strickler, Sang-We Kim, Stephen Clarke, Thomas J. George, Peter S. Grimison, Minal Barve, Manik Amin, Jayesh Desai, Trisha Wise-Draper, Steven Eck, Yu Jiang, Anis A. Khan, Yuling Wu, Philip Martin, Zachary A. Cooper, Nairouz Elgeioushi, Nancy Mueller, Rakesh Kumar, Sandip Pravin Patel
Summary: This study evaluated the use of oleclumab in patients with advanced colorectal cancer, pancreatic ductal adenocarcinoma, and epidermal growth factor receptor-mutant non-small-cell lung cancer. The results showed that oleclumab had a manageable safety profile and demonstrated antitumor activity.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
Tamkin Ahmadzada, Abhishek Vijayan, Fatemeh Vafaee, Ali Azimi, Glen Reid, Stephen Clarke, Steven Kao, Georges E. Grau, Elham Hosseini-Beheshti
Summary: In this study, we characterized different populations of extracellular vesicles (EVs) derived from pleural mesothelioma cell lines and identified unique cancer-specific proteomes and oncogenic cargo in each subtype. We also established a comprehensive proteomic database of cancer-associated proteins in EVs, which could serve as new targets for future biomarker studies in pleural mesothelioma.
Article
Biochemistry & Molecular Biology
Joe Q. Q. Wei, Alexander Yuile, Malinda Itchins, Benjamin Y. Y. Kong, Bob T. T. Li, Nick Pavlakis, David L. L. Chan, Stephen J. J. Clarke
Summary: Platinum-based chemotherapy combined with anti-PD-1 or PD-L1 monoclonal antibodies is the standard first-line therapy for mNSCLC patients without sensitizing driver mutations. Using network meta-analysis, we compared the efficacy of these two antibodies indirectly due to the absence of head-to-head randomized control trials. The results showed that anti-PD-1 mAb + chemotherapy had superior overall survival, progression-free survival, and objective response rate compared to anti-PD-L1 mAb + chemotherapy, with similar rates of grade 3 and higher toxicities. However, head-to-head RCTs are still needed in the future.
Meeting Abstract
Gastroenterology & Hepatology
Stuart Keith Roberts, Ashika Maharaj, John Lubel, Eileen Lam, Paul J. Clark, Oliver Duncan, Jacob George, Gary P. Jeffrey, Lara Lipton, Howard Liu, Geoffrey McCaughan, Eu-Ling Neo, Jenny Philip, Simone I. Strasser, Katherine Stuart, Alexander Thompson, Jonathan Tibbals, Thomas Tu, Michael C. Wallace, Alan Wigg, Marnie Wood, Amany Zekry, Elysia Greenhill, Liane J. Ioannou, Golo Ahlenstiel, Kaye Bowers, Stephen J. Clarke, Anouk Dev, Mark Goodwin, Christos Karapetis, Miriam T. Levy, Kate Muller, James Patrick O'Beirne, David Pryor, James Seow, Caroline J. Tallis, Nick Butler, John K. Olynyk, John Zalcberg
Article
Gastroenterology & Hepatology
Ashika D. Maharaj, John Lubel, Eileen Lam, Paul J. Clark, Oliver Duncan, Jacob George, Gary P. Jeffrey, Lara Lipton, Howard Liu, Geoffrey McCaughan, Eu-Ling Neo, Jennifer Philip, Simone Strasser, Katherine Stuart, Alexander Thompson, Jonathan Tibballs, Thomas Tu, Michael C. Wallace, Alan Wigg, Marnie Wood, Amany Zekry, Elysia Greenhill, Liane J. Ioannou, Golo Ahlenstiel, Kaye Bowers, Stephen J. Clarke, Anouk Dev, Michael Fink, Mark Goodwin, Christos S. Karapetis, Miriam T. Levy, Kate Muller, James O'Beirne, David Pryor, James Seow, Nicholas Shackel, Caroline Tallis, Nick Butler, John K. Olynyk, Kate Reed-Cox, John R. Zalcberg, Stuart K. Roberts
Summary: This study aimed to develop a core set of quality indicators for the management of hepatocellular carcinoma (HCC). Through a Delphi consensus study, 23 specific indicators were identified, covering aspects such as diagnosis, staging, and treatment of HCC. Adherence to these indicators can improve the quality of care and patient outcomes, including survival.
HEPATOLOGY COMMUNICATIONS
(2022)
